ArticlePregnancy (Hoboken, N.J.)2026
Optimizing longitudinal follow-up after hypertensive disorders of pregnancy: A quality improvement initiative.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hypertensive disorders of pregnancy (HDP) are associated with increased risk for future cardiovascular disease. Guidelines recommend longitudinal follow-up for cardiovascular risk stratification after pregnancy complicated by HDP; however, adherence to this recommendation remains suboptimal. Our aim was to evaluate the impact of the Postpartum Hypertension Program (PHP), a quality improvement initiative designed to address patient, clinician, and system barriers to longitudinal follow-up after HDP. Methods: This was a retrospective cohort study evaluating rates of longitudinal follow-up before and after PHP implementation at a level IV maternal care center. Individuals were eligible if they had a diagnosis of HDP and were discharged on antihypertensive medication after delivery. A post-implementation cohort (eligible individuals referred to the PHP with delivery discharge from January 21, 2024 to March 22, 2025) was compared to a pre-implementation cohort (all eligible individuals with delivery discharge from January 1, 2021 to January 20, 2024). The primary outcome was follow-up with a longitudinal clinician (Cardiology, Internal Medicine, or Family Medicine) within 1 year postpartum. Secondary outcomes included rates of longitudinal follow-up at 3 and 6 months postpartum and patient characteristics associated with 1-year follow-up. Program components included: (1) clinician education, (2) patient education, and (3) a streamlined process for transfer-of-care to a longitudinal clinician. Data were abstracted from the medical record. Bivariate analysis compared outcomes between cohorts, and multivariable logistic regression was used to adjust for potential confounders. Results: A total of 227 individuals met inclusion criteria (pre-implementation: Conclusion: PHP implementation was associated with 2.6-fold increased odds of longitudinal follow-up within 1 year after pregnancy complicated by HDP. With adequate infrastructure and resources, this program can serve as a model for institutions seeking to improve longitudinal care transitions for individuals with HDP. Further study is needed to determine the impact of improved follow-up rates on long-term cardiovascular health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.